Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo takes on rare, Drug-Resistant lung bug

NCT ID NCT07485010

Not yet recruiting Disease control Sponsor: The University of Queensland Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests a new combination of antibiotics (called Arm D) against standard treatments for a rare lung infection caused by Mycobacterium abscessus. About 300 people with or without cystic fibrosis will take part. The goal is to see if the new combo clears the infection better and with fewer side effects over a shorter treatment period.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sulbactam-durlobactam plus ceftriaxone, amoxicillin, azithromycin, and clofazimine
What this could lead to
If it works, this could point toward a more effective treatment for a hard-to-treat lung infection, potentially reducing treatment duration and side effects.
What could go wrong
This is an early phase 2 trial with only 300 participants, so results may not apply to everyone. The new combination may not clear the infection better than current treatments and could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM ABSCESSUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections mycobacterial infectious disease Mycobacterium Infections, Nontuberculous pulmonary non-tuberculous mycobacterial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYCOBACTERIUM ABSCESSUS INFECTION MYCOBACTERIUM ABSCESSUS PULMONARY DISEASE NON-TUBERCULOUS MYCOBACTERIA PULMONARY DISEASE NON-TUBERCULOUS MYCOBACTERIAL (NTM) INFECTIONS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.